Wall Street analyst estimates for Coeptis Therapeutics Holdings, Inc. (COEP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-05-14 | $-1.11 | ||
| 2026-03-19 | $-0.12 | $-0.80 | +85.0% |
| 2025-11-13 | $-0.58 | ||
| 2025-08-14 | $-1.17 | ||
| 2025-05-14 | $-1.11 | ||
| 2025-03-28 | $-1.01 | $-0.80 | -26.5% |
| 2024-11-13 | $-0.05 | $-0.05 | +0.0% |
| 2024-08-16 | $-0.08 | $-0.09 | +11.1% |
Valuation Ratios
| Price / Book | 3.50 |
| EV / EBITDA | -5.28 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2004 | 2005 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $30761 | $75000 | 0 | 0 | 0 | $1.4M |
| Cost of Revenue | 0 | 0 | 0 | 0 | $964217 | 0 | 0 | 0 | 0 | $180625 |
| Gross Profit | 0 | 0 | 0 | 0 | -$933456 | $75000 | 0 | 0 | 0 | $1.2M |
| Research & Development | 0 | 0 | 0 | 0 | $3543 | 0 | $20887 | $6.7M | $2.3M | $1.3M |
| Selling, General & Admin | $10077 | $308305 | 0 | 0 | $5.8M | $14.1M | $34.2M | $13.8M | $6.7M | $11.9M |
| Operating Expenses | $10077 | $308305 | 0 | 0 | $5.9M | $14.1M | $34.2M | $21.5M | $10.1M | $14.2M |
| Operating Income | -$10077 | -$308000 | 0 | 0 | -$6.9M | -$14.0M | -$34.2M | -$21.5M | -$10.1M | -$13.0M |
| EBITDA | $2.6M | -$308000 | -$7070 | $171860 | -$8.7M | -$12.8M | -$36.4M | -$20.1M | -$9.4M | -$10.4M |
| Interest Expense | 0 | 0 | 0 | 0 | $148192 | $187133 | $218412 | $107685 | $396116 | $642379 |
| Pre-tax Income | $2.6M | 0 | -$7073 | -$2234 | -$9.2M | -$13.4M | -$37.6M | -$21.3M | -$10.9M | -$12.3M |
| Income Tax | 0 | $36000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $2.6M | -$344000 | -$7073 | -$2234 | -$9.2M | -$13.4M | -$37.6M | -$21.3M | -$10.7M | -$11.9M |
| EPS | $1421.16 | $-184.81 | $-0.01 | $-0.00 | $-0.45 | $-13.16 | $-2.87 | $-0.83 | $-5.65 | $-2.81 |
| EPS (Diluted) | $1421.16 | $-184.81 | $-0.01 | $-0.00 | $-0.45 | $-13.16 | $-2.87 | $-0.83 | $-5.65 | $-2.81 |
| Shares Outstanding (Diluted) | $1863 | $1863 | $539062 | $10.8M | $20.4M | $1.0M | $14.3M | $25.7M | $1.9M | $4.2M |
Price
| Price | $10.99 |
| Market Cap | $39M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CUE · EQ · IPSC · KPTI · MDCX · NRXP · OSTX
Explore sector: Technology · Software - Services
More sections of COEP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks